Literature DB >> 30551380

Preventive effect of trans-chalcone on non-alcoholic steatohepatitis: Improvement of hepatic lipid metabolism.

Elham Karimi-Sales1, Abbas Ebrahimi-Kalan2, Mohammad Reza Alipour3.   

Abstract

Non-alcoholic steatohepatitis (NASH) is an inflammatory and progressive form of non-alcoholic fatty liver disease. However, there are no FDA-approved drugs for this condition. Lipids accumulated in NASH have a direct role in the progression of this disease. Therefore, this study for the first time explored the preventive effect of trans-chalcone on NASH through the modulation of sterol regulatory element binding protein (SREBP)-1c, SREBP-2, hepatic fatty acid synthesis (FAS) enzyme, proliferator-activated receptor (PPAR)-α, and PPAR-γ2 levels, which are involved in hepatic lipid metabolism. In this study, male rats were randomly divided into three groups (n = 7): Control, received 10% tween 80; NASH, received 10% tween 80 and 10 ml/kg high-fat emulsion (high-fat diet, HFD); and NASH + TC, received 20 mg/kg trans-chalcone and 10 ml/kg HFD. All treatments were performed by once-daily oral gavage for 6 weeks. Liver and blood samples were collected and serum levels of alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), triglyceride, total cholesterol, low-density lipoprotein (LDL)-cholesterol, and high-density lipoprotein (HDL)-cholesterol, as well as hepatic levels of SREBP-1c, SREBP-2, FAS, PPAR-α, and PPAR-γ2, were measured. Moreover, hematoxylin and eosin stained tissues were used for histological analysis. In this study, treatment of HFD-fed rats with trans-chalcone significantly reduced abnormalities in liver histology, serum levels of liver injury markers, liver index, and hepatic levels of SREBP-1c, SREBP-2, FAS, and PPAR-γ2. Furthermore, trans-chalcone significantly increased hepatic PPARα levels in these rats. Therefore, it seems that trans-chalcone protects the liver of HFD-fed rats against NASH development through reduction of SREBP-1c/ FAS- and PPAR-γ2-related lipogenesis, attenuation of SREBP-2-related cholesterol synthesis, and elevation of PPARα-related fatty acid oxidation.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  FAS, PPARs; Liver; NASH; SREBPs; trans-Chalcone

Mesh:

Substances:

Year:  2018        PMID: 30551380     DOI: 10.1016/j.biopha.2018.10.196

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  3 in total

1.  Discovery of JND003 as a New Selective Estrogen-Related Receptor α Agonist Alleviating Nonalcoholic Fatty Liver Disease and Insulin Resistance.

Authors:  Liufeng Mao; Lijie Peng; Xiaomei Ren; Yi Chu; Tao Nie; Wanhua Lin; Xuemei Zhao; Andrew Libby; Yong Xu; Yu Chang; Chong Lei; Kerry Loomes; Na Wang; Jinsong Liu; Moshe Levi; Donghai Wu; Xiaoyan Hui; Ke Ding
Journal:  ACS Bio Med Chem Au       Date:  2022-01-31

2.  Effects of 2',6'-dihydroxy-4'-methoxydihidrochalcone on innate inflammatory response.

Authors:  Murilo Luiz Cerutti; Larissa Benvenutti; Roberta Nunes; Silvia Ramos da Silva; Sara Cristiane Barauna; Márcia Maria de Souza; Ângela Malheiros; Letícia Lacava; Nara Lins Meira Quintão; José Roberto Santin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-06-16       Impact factor: 3.000

3.  Protective Role of trans-Chalcone against the Progression from Simple Steatosis to Non-alcoholic Steatohepatitis: Regulation of miR-122, 21, 34a, and 451.

Authors:  Elham Karimi-Sales; Sajad Jeddi; Abbas Ebrahimi-Kalan; Mohammad Reza Alipour
Journal:  Adv Pharm Bull       Date:  2021-01-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.